Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Review of the SELECT-AML-1 Trial and the Future of Newly Diagnosed AML

July 6th 2022

Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.

Tisa-cel Adds a Potential New ‘Standard-of-Care’ in Third-Line Treatment of Follicular Lymphoma

July 6th 2022

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

Brexucabtagene Autoleucel Has Durable Efficacy in B-ALL, Irrespective of Age and Tumor Burden

July 4th 2022

Bijal Shah, MD, MS, discusses the long-term data from the ZUMA-3 trial of brexucabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and spotlighted additional areas ripe for further exploration.

FDA Issues Warning for Increased Risk of Death, Serious AEs with Duvelisib in CLL/SLL

July 1st 2022

The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Grants Orphan Drug Designation to Evorpacept for AML

July 1st 2022

The FDA has granted an orphan drug designation to evorpacept, a next-generation CD47 blocker, for use as a potential therapeutic option for patients with acute myeloid leukemia.

FDA Approval Sought for Subcutaneous Epcoritamab for Relapsed/Refractory LBCL

July 1st 2022

Genmab A/S shared plans to submit a biologics license application to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed or refractory large B-cell lymphoma in the second half of 2022.

More Novel Therapies Are on the Horizon in Multiple Myeloma

July 1st 2022

Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma.

Improving Outcomes in Patients With DLBCL

June 30th 2022

Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.

A Focus on Frontline Treatment in Patients With DLBCL

June 30th 2022

Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.

Optimizing Frontline Therapy in ITP: Treatment Selection and Goals

June 30th 2022

Shared insight on treatment goals for immune thrombocytopenia and how physicians might optimally select frontline therapy.

Making a Diagnosis of Immune Thrombocytopenia

June 30th 2022

Opening their discussion on immune thrombocytopenia (ITP), expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Orelabrutinib/Sintilimab Combo Induces Rapid Responses in Peripheral CNS Lymphoma

June 29th 2022

The addition of orelabrutinib to sintilimab demonstrated good efficacy with a rapid time to response in patients with relapsed/refractory primary central nervous system lymphoma.

CDK9 Inhibitor GFH009 Advances in Phase 1 Trial in Relapsed/Refractory Lymphoma and AML

June 28th 2022

The novel and highly selective CDK9 inhibitor GFH009 demonstrated encouraging tolerability in patients with advanced, relapsed/refractory acute myeloid leukemia and lymphoma.

Axi-cel Gains European Approval for Relapsed/Refractory Follicular Lymphoma

June 28th 2022

The European Commission has granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after 3 or more prior lines of systemic therapy.

Venetoclax and HMA Resistance in Patients with AML

June 28th 2022

Dr Daniel Pollyea discusses the role of venetoclax plus an HMA agent in patients with AML and talks about some possible mechanisms of resistance to the venetoclax-HMA combination.

Teclistamab Elicits Survival Benefit vs Real-World Treatment in Multiple Myeloma

June 28th 2022

Teclistamab demonstrated superiority over physician’s choice of therapy for overall survival, progression-free survival, and time to next treatment in patients with relapsed/refractory multiple myeloma.

Potential Role of Tamibarotene in AML

June 28th 2022

Daniel Pollyea, MD, MS, reviews the initial results from the biomarker-directed phase 2 tamibarotene trial that were presented at ASH 2020.

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Dr. Ghosh on the Safety Data Seen With Liso-cel in LBCL

June 27th 2022

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.